CR9647A - Moduladores de cinasa de aminoquinolina y amoniquinazolina - Google Patents

Moduladores de cinasa de aminoquinolina y amoniquinazolina

Info

Publication number
CR9647A
CR9647A CR9647A CR9647A CR9647A CR 9647 A CR9647 A CR 9647A CR 9647 A CR9647 A CR 9647A CR 9647 A CR9647 A CR 9647A CR 9647 A CR9647 A CR 9647A
Authority
CR
Costa Rica
Prior art keywords
compounds
aminoquinoline
trkb
flt3
amoniquinazoline
Prior art date
Application number
CR9647A
Other languages
English (en)
Inventor
Baindur Nand
David Gaul Michael
Douglas Kreutter Kevin
Andrew Baumann Chiristian
Xu Guozhang
J Kim Alexander
Zhao Bao-Ping
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37101582&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR9647(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of CR9647A publication Critical patent/CR9647A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La invencion esta dirigida a compuestos de aminoquinolina y aminoquinazolina de la formula I, en donde R1, R2, R3, B, Z, Q, p, q y X son como se define aqui, el uso de dichos compuestos como moduladores de proteina tirosina cinasa, particularmente inhibidores de FLT3 y/o TrkB, el uso de dichos compuestos para reducir o inhibir la actividad de cinasa de FLT3 y/o TrkB en una celula o un sujeto, y el uso de dichos compuestos para prevenir o tratar en un sujeto un trastorno proliferativo de celulas y/o trastornos relacionados con FLT3 y/o TrkB; la presente invencion ademas esta dirigida a composiciones farmaceuticas que comprenden los compuestos de la presente invencion y a metodos para tratar condiciones tales como canceres y otros trastornos proliferativos de celulas.
CR9647A 2005-06-10 2008-01-09 Moduladores de cinasa de aminoquinolina y amoniquinazolina CR9647A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68938205P 2005-06-10 2005-06-10
US74732106P 2006-05-16 2006-05-16

Publications (1)

Publication Number Publication Date
CR9647A true CR9647A (es) 2008-09-09

Family

ID=37101582

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9647A CR9647A (es) 2005-06-10 2008-01-09 Moduladores de cinasa de aminoquinolina y amoniquinazolina

Country Status (17)

Country Link
US (1) US20070004763A1 (es)
EP (1) EP1899319A2 (es)
JP (1) JP2008543762A (es)
KR (1) KR20080028913A (es)
AR (1) AR057062A1 (es)
AU (1) AU2006258059A1 (es)
BR (1) BRPI0611621A2 (es)
CA (1) CA2611378A1 (es)
CR (1) CR9647A (es)
EA (1) EA200800014A1 (es)
EC (1) ECSP077998A (es)
GT (1) GT200600254A (es)
IL (1) IL187685A0 (es)
NO (1) NO20080168L (es)
PE (1) PE20070113A1 (es)
TW (1) TW200716598A (es)
WO (1) WO2006135649A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080076770A1 (en) * 2006-09-25 2008-03-27 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
UY36391A (es) 2014-11-05 2016-06-01 Flexus Biosciences Inc Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido1), sus métodos de síntesis y composiciones farmacèuticas que las contienen
US10111885B2 (en) * 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
TW201726675A (zh) 2015-12-23 2017-08-01 默沙東藥廠 M4毒蕈鹼乙醯膽鹼受體之異位調節劑6,7-二氫-5h-吡咯并[3,4-b]吡啶-5-酮
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
WO2017192813A1 (en) * 2016-05-04 2017-11-09 Bristol-Myers Squibb Company Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
US10414775B2 (en) 2016-08-15 2019-09-17 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
WO2018034918A1 (en) * 2016-08-15 2018-02-22 Merck Sharp & Dohme Corp. Compounds useful for altering the levels of bile acids for the treatment of diabetes and cardiometabolic disease
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112840A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000237A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
KR20240151869A (ko) 2017-09-08 2024-10-18 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 Enpp1 저해제 및 암의 치료용의 이의 용도
US11447493B2 (en) 2018-05-02 2022-09-20 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
EP3813819A4 (en) 2018-06-29 2022-08-17 Kinnate Biopharma Inc. CYCLIN-DEPENDENT KINASE INHIBITORS
US20220363667A1 (en) * 2018-07-17 2022-11-17 Nippon Chemiphar Co., Ltd. T-type calcium channel blocker
JP2022081710A (ja) * 2019-03-29 2022-06-01 ユーティアイ リミテッド パートナーシップ 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用
AU2020250468A1 (en) * 2019-03-29 2021-11-04 Kinki University Use of T-type calcium channel blocker for treating pruritus
CA3147422A1 (en) * 2019-07-17 2021-01-21 Kinnate Biopharma Inc. Inhibitors of cyclin-dependent kinases
US20230339936A1 (en) * 2020-07-23 2023-10-26 Cytosinlab Therapeutics Co. Ltd. Compound having kinase inhibitory activity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT344178B (de) * 1974-07-25 1978-07-10 Pfizer Verfahren zur herstellung von neuen chinazolinverbindungen und deren saeureadditionssalzen und optisch aktiven formen
JP3169188B2 (ja) * 1991-01-31 2001-05-21 杏林製薬株式会社 カルバミン酸誘導体及びその製造方法
US7074801B1 (en) * 2001-04-26 2006-07-11 Eisai Co., Ltd. Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
BR0312204A (pt) * 2002-06-27 2005-04-26 Schering Ag Antagonista de receptor ccr5 de quinolina substituìda
JP4845736B2 (ja) * 2003-10-14 2011-12-28 アリゾナ ボード オブ リージェンツ オン ビハーフ ザ ユニバーシティー オブ アリゾナ プロテインキナーゼ阻害剤

Also Published As

Publication number Publication date
ECSP077998A (es) 2008-01-23
IL187685A0 (en) 2008-08-07
WO2006135649A3 (en) 2007-02-15
GT200600254A (es) 2007-01-12
EP1899319A2 (en) 2008-03-19
AR057062A1 (es) 2007-11-14
TW200716598A (en) 2007-05-01
BRPI0611621A2 (pt) 2010-09-21
US20070004763A1 (en) 2007-01-04
AU2006258059A1 (en) 2006-12-21
NO20080168L (no) 2008-03-07
KR20080028913A (ko) 2008-04-02
JP2008543762A (ja) 2008-12-04
WO2006135649A2 (en) 2006-12-21
EA200800014A1 (ru) 2008-06-30
PE20070113A1 (es) 2007-02-09
CA2611378A1 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
CR9647A (es) Moduladores de cinasa de aminoquinolina y amoniquinazolina
ECSP077994A (es) Aminopirimidinas como moduladores de cinasa
ECSP077991A (es) Aminopirimidinas como moduladores de cinasa
NI200800179A (es) Triazolopiridazinas como moduladores de la tirosina cinasa
CR9652A (es) Moduladores de alquilquinolina y alquilquinazolina cinasa
CR9650A (es) Derivados de tienopirimidina y tienopiridina como inhibidores de tirosina cinasa 3 tipo fms
ECSP088823A (es) Quinazolinas para la inhibición de pdk1
EA201100425A1 (ru) Производные пиколинамида в качестве ингибиторов киназы
CO6270257A2 (es) Derivados de piridazinona
CL2011002946A1 (es) Compuestos derivados de tiazoltiadiazol aminopirazol, inhibidores de proteina quinasa c-met; composicion farmaceutica que los comprende y su uso en el tratamiento de diferentes tipos de cancer.
EA200702136A1 (ru) Композиции станнсопорфина и их применение
UY29587A1 (es) Moduladores de aminoquinolina y aminoquinazolina quinasa
GT200600250A (es) Moduladores de quinasas con estructuras de alquilquinolina y alquilquinazolina referencia cruzada con solicitudes relacionadas
UY29592A1 (es) Aminopirimidinas como moduladores de quinasas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)